Obvius Pharma

Obvius Pharmaceuticals was a specialty pharmaceutical company based in Bridgewater, New Jersey, focused on the development and commercialization of high-value generic drug products. The company specialized in complex generics, particularly those with high barriers to entry, such as first-to-file and first-to-market opportunities. Obvius was notably involved in the development of Lidocaine Patch 5%, a generic version of Lidoderm used for the treatment of post-herpetic neuralgia. In January 2021, the company was acquired by Amneal Pharmaceuticals for an upfront payment of 15 million dollars plus potential contingent considerations. This acquisition allowed Amneal to strengthen its portfolio of complex generic products and enhance its research and development pipeline.